Open-Label Extension Study to Pioneer Study 6058-SCD-101

Official title

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of Pociredir in Participants With Sickle Cell Disease (SCD) Who Have Participated in a Pociredir Study

Overview

This is an open-label study to evaluate the safety and tolerability of long-term treatment with pociredir without a comparator in participants with SCD who have previously been treated and shown benefit with pociredir in feeder study 6058-SCD-101 (NCT05169580). Participants in this study will receive once daily doses of pociredir for up to 48 months.

Detailed description

The first dose of study drug will be administered on Day 1 in the clinic and participants will continue at home dosing once daily (QD). Dosing will occur in the clinic on days where there are clinic visits. Treatment Period clinic visits are planned every other week through Week 12 (Weeks 2, 4, 6, 8, 10, and 12), monthly through Week 24 (Weeks 16, 20, and 24), and then every 12 weeks from Week 24 through Week 192. A final follow-up visit (Week 196) will occur 4 weeks after the final dose of study drug at Week 192.

Participants will receive pociredir at the dose level they received in Study 6058-SCD-101 through Week 192, unless data from that study indicates a change to a different optimized dose.

Interventions

• Drug Pociredir
  Pociredir Oral Capsules will be administered

Primary outcome measures

• Number of participants reporting Treatment Emergent Adverse Events (TEAEs) [Time frame: Up to Week 196]
• Number of participants with clinically significant changes in 12-lead Electrocardiogram (ECGs) [Time frame: Up to Week 196]
• Number of participants with clinically significant changes in Vital signs [Time frame: Up to Week 196]
• Number of participants with clinically significant changes in Clinical laboratory tests [Time frame: Up to Week 196]

Secondary outcome measures (9)

• Change from Baseline in percent Fetal hemoglobin (HbF) [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in percent Reticulocytes [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in Red cell distribution width [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in Unconjugated bilirubin [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in Lactate dehydrogenase (LDH) [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in Haptoglobin [Time frame: Baseline (Day 1), and Up to Week 192]
• Change from Baseline in Reticulocyte count [Time frame: Baseline (Day 1), and Up to Week 192]
• Number of participants reporting SCD-related complications [Time frame: Up to Week 192]
• Annualized rate of Vaso-occlusive episode (VOE) [Time frame: through end of month 48]

Eligibility criteria

Inclusion criteria

• Participants aged ≥18 years and older must have previously participated in and successfully completed Study 6058-SCD-101.
• Participant has signed and dated the informed consent form (ICF) before any study-specific procedures are performed and is willing and able to comply with the study procedures and restrictions.
• Participants who meet all other inclusion and exclusion criteria for this study, and per Investigator's recommendation may continue standard of care as indicated with the exception of hydroxyurea (HU). Participants may continue crizanlizumab, and/or L-glutamine, but must be on a stable dose for at least 6 months.
• Participants, who if female and of childbearing potential, agree to use 2 effective methods of contraception, 1 of which must be highly effective, or practice abstinence starting at the time of the ICF signing to 90 days after the last dose of study drug, and, who if male, should use condoms or practice abstinence from the time of ICF signing to 90 days after the last dose of study drug.
• Documented HbF benefit, as judged by the Investigator, from prior study.
• Participant must meet both of the following laboratory values during Screening:

• Absolute neutrophil count ≥ 1.5 × 10\^9/liter,
• Platelets ≥ 80 × 10\^9/liter
• Absolute reticulocyte count during Screening > 100 × 10\^9/liter.

Exclusion criteria

• Major surgery, serious illness (acute or chronic), infection (clinically significant bacterial, fungal, parasitic or viral infection which requires therapy), fever not resolved within 3 days of onset and requiring treatment, significant bleeding, cerebrovascular accident, or seizure within 14 days prior to signing the ICF and 14 days prior to starting study drug.
• Sickle cell complication requiring more than 24-hour care from a medical provider in hospital or emergency care setting in the 14 days prior to starting study drug.
• Use of medications that are moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A4 or CYP2C8, inhibit P-glycoprotein, breast cancer resistance protein, or multidrug and toxin extrusion protein 2-K, or are substrates of CYP2B6 within 14 days prior to first dose of study drug or anticipated need for any of these medications during the study.
• Participation in any other study with an investigational agent other than pociredir within the past 60 days prior to the first dose of study drug.
• History of bone marrow transplant or hematopoietic stem cell transplant or gene therapies.
• Vaccination in the previous 7 days prior to the first dose of study drug.

Note: Other protocol specified criteria may apply

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 8 centers

• University of Arkansas for Medical Sciences — Little Rock
• University of California, Los Angeles — Los Angeles
• Our Lady of the Lake Hospital — Baton Rouge
• Boston Medical Center — Boston
• Queens Hospital Cancer Center — Jamaica
• Jacobi Medical Center — The Bronx
• University of Texas Houston — Houston
• Inova Schar Cancer Institute — Fairfax

Identifiers

NCT: NCT07401823 · 6058-SCD-102

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗